Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CardioCell
- Development stage
- Unknown
- Lead developer
- CardioCell
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intracoronary
01
Overview
CardioCell is an allogeneic, cell-based regenerative therapy consisting of mesenchymal stem cells (MSCs) isolated from Wharton's jelly, the umbilical cord matrix. Developed by researchers at John Paul II Hospital and Jagiellonian University Medical College in Krakow as part of the CIRCULATE project, it is classified as an advanced therapy medicinal product (ATMP). The therapy is designed as an 'off-the-shelf' standardized therapeutic agent for the treatment of acute myocardial infarction (AMI) and other ischemic cardiovascular conditions, such as critical limb ischemia. CardioCell functions through multiple paracrine mechanisms, including the promotion of angiogenesis, inhibition of apoptosis, reduction of inflammation via the secretion of anti-inflammatory cytokines and chemokines, and the exertion of antifibrotic effects to facilitate the repair of damaged cardiovascular tissue.
- Brand names
- CardioCell
- Other names
- Wharton's jelly mesenchymal stem cellsWJMSCAllogeneic mesenchymal stem cells
Beyond the preview
Go deeper on CardioCell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CardioCell.